D.A. Wallach – Investing in Healthcare - [Invest Like the Best, EP.166]

Episode Summary

Executive Summary: Patrick O'Shaughnessy interviews investor D.A. Wallach on how biology, data, and incentives are reshaping healthcare investing—from gene editing and early detection to pricing, delivery, and venture exits—while weaving in his own personal health journey and past in music.

Main Topics: Why Wallach Entered Healthcare (Priority: 9/5): He saw consumer healthcare as an under-modernized experience with huge impact and return potential. Biopharma vs. Healthcare Delivery (Priority: 8/5): He splits the sector into medicine products and the systems that deliver them to patients. New Biology Tools and Medicine 2.0 (Priority: 10/5): Sequencing, RNA/protein tools, and editing technologies are shifting medicine from symptom control to cures. Personalized Prevention and Monitoring (Priority: 8/5): Wearables, baselines, and continuous sensing aim to detect disease earlier and tailor care. Venture Investing in Life Sciences (Priority: 9/5): Big pharma’s R&D retreat created a forced-buyer market for startups and defined his exit-driven process. Drug Pricing and Healthcare Opaqueness (Priority: 8/5): He argues prices are distorted by rebates, monopolies, and weak price discovery rather than simple greed. Music, Spotify, and Distribution (Priority: 5/5): His music background taught him how distribution shifts power, a pattern he sees recurring in media and healthcare.

Key Arguments: Healthcare is under-modernized; even healthy patients have a poor experience. Medicine is moving from symptom control to cure and prevention. DNA sequencing cost collapse enabled scale biology research. Gene editing can be ethical when used first for clearly suffering patients. Big pharma now relies on acquisitions, creating a structural exit path for biotechs. Hospitals and drug supply chains exhibit monopolies and weak price discovery. Delivery innovation is harder than product innovation, so PE/growth fits better there.

Data Points: Human genome sequencing cost: $3 billion to a couple hundred dollars - Used to illustrate the collapse in sequencing costs and the rise of biology tools. Chance of cancer: 80% plus chance - Wallach describes his wife's MLH1 mutation and associated lifetime cancer risk. Pharma startup acquisition market: $20 to $30 billion worth of startups - He says big pharma buys this amount annually and will keep needing acquisitions. Google Ventures healthcare/life sciences share: 60% - Wallach cites GV allocating most of its investments to healthcare and life sciences. Project Baseline cohort: as many as 100,000 people - Google's project measures biomarkers repeatedly to establish healthy baselines. List price example: $100 - He explains the drug pricing chain with a hypothetical pharmacy transaction. Rebate example: $80 rebate - Illustrates how list prices can rise while net prices differ materially. Cell therapy manufacturing cost: $200,000 or $300,000 cost - He cites high COGS for patient-specific cancer cell therapies. Time horizon for venture investing: 5 to 10 years - He contrasts venture return horizons with long-term scientific visions. Historical medicine biology era: 200 years - He notes modern biology and medicine are only about two centuries old. Human existence: 300,000 years - Used to emphasize how recent modern biological understanding is.

Pivotal Quotes: "we're entering really the second great historical era of medicine and biology" — D.A. Wallach: He frames the current transformation as a once-in-history shift in understanding life. "It's much easier to get into venture investments than it is to get out of them." — D.A. Wallach: He explains why exits, not just ideas, drive his investing process. "there is a whole mess of incentives that is leading these prices to go up" — D.A. Wallach: He summarizes his view on drug pricing and why the system looks inflated.

Implications: The next frontier is better prediction and prevention; investors should watch where biology, reimbursement, and commercialization align first.